[시장보고서]세균 및 바이러스 검체 채취 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

세균 및 바이러스 검체 채취 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Bacterial And Viral Specimen Collection Market Size, Share, & Trends Analysis Report By Product (Bacterial Specimen Collection, Viral Specimen Collection), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1750875

리서치사 : Grand View Research, Inc.

발행일 : 2025년 05월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,134,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 9,501,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,235,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

세균·바이러스 검체 채취 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 세균·바이러스 검체 채취 시장 규모는 2030년까지 333억 7,000만 달러에 달하며, 2025-2030년의 CAGR은 14.5%로 확대할 것으로 예측됩니다.

COVID-19, 독감, 결핵 등 감염성 질환 증가로 인해 세균 및 바이러스 검체 채취에 대한 수요가 크게 증가하고 있습니다. 의료 시스템이 발병을 억제하고 환자 결과를 개선하기 위해 노력하는 가운데, 정부와 민간 부문은 의료에 대한 투자를 강화하고 있습니다. 이러한 의료 지출의 급증은 진단 검사 확대, 인프라 개선, 효율적인 검체 채취 툴 개발을 지원하며, 궁극적으로 시장 개발의 원동력이 되고 있습니다.

PCR, 분자 분석, 신속 검사 플랫폼 등 진단 기술의 발전은 감염성 질환의 검출 방법을 완전히 바꾸어 놓았습니다. 이러한 기술 혁신은 정확성을 보장하기 위해 신뢰할 수 있는 고품질 검체 채취 방법을 필요로 합니다. 또한 조기 및 정확한 진단의 중요성에 대한 의료진과 환자들의 인식이 높아지면서 검사 건수가 증가하여 고급 검체 채취 툴에 대한 수요가 증가하여 전체 시장 규모가 확대되고 있습니다.

재택 검사와 현장 진단의 편의성과 접근성에 힘입어 분산형 의료로의 전환은 검체 채취의 상황을 재구성하고 있습니다. 이러한 추세는 전통적인 검사실에 대한 의존도를 낮추고 검체 채취 빈도를 증가시키고 있습니다. 또한 백신, 치료제, 감염병 감시를 위한 연구 및 임상시험의 확대는 표준화된 검체 채취 키트에 대한 수요를 증가시켜 시장 성장에 크게 기여하고 있으며, 다양한 분야로의 적용을 확대하고 있습니다.

세균 및 바이러스 검체 채취 시장 보고서 하이라이트

제품별로는 바이러스 검체 채취 부문이 2024년 57.3%의 최대 매출 점유율로 시장을 주도했습니다.
용도별로는 진단 분야가 2024년 가장 큰 점유율을 차지하며 시장을 장악했습니다.
연구 분야는 검체 분석의 정확성과 효율성을 높이는 차세대 시퀀싱, 멀티플렉스 PCR과 같은 진단 툴의 기술 발전으로 인해 2025-2030년 크게 성장할 것으로 예측됩니다.
편리하고 개인적이며 접근성이 좋은 진단 솔루션에 대한 소비자 수요 증가에 힘입어 재택 검사 분야는 예측 기간 중 가장 빠른 성장세를 보일 것으로 예측됩니다.
북미는 높은 전염병 발병률, 막대한 헬스케어 투자, 첨단 인프라, 강력한 R&D 구상에 힘입어 2024년 45%의 최대 매출 점유율을 차지했습니다.

부문 대시보드
세균·바이러스 검체 채취 시장 : 변동 분석
세계의 세균·바이러스 검체 채취 시장 규모와 동향 분석(2018-2030년)
세균 표본 수집
- 스왑
- 세균 운송 배지
- 채혈 키트
- 기타 소모품
바이러스 검체 채취
- 스왑
- 바이러스 운송 매체
- 채혈 키트
- 기타 소모품

제5장 세균·바이러스 검체 채취 시장 : 용도 추정·동향 분석

부문 대시보드
세균·바이러스 검체 채취 시장 : 변동 분석
세계의 세균·바이러스 검체 채취 시장 규모와 동향 분석(2018-2030년)
진단
연구

제6장 세균·바이러스 검체 채취 시장 : 최종 용도 추정·동향 분석

부문 대시보드
세균·바이러스 검체 채취 시장 : 변동 분석
세계의 세균·바이러스 검체 채취 시장 규모와 동향 분석(2018-2030년)
병원과 진료소
자택 검사
실험실

제7장 세균·바이러스 검체 채취 시장 : 지역 추정·동향 분석

지역 시장 대시보드
지역별 시장 점유율 분석, 2024년 및 2030년
지역별 세균·바이러스 검체 채취 시장 : 주요 포인트
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

주요 시장 참여 기업에 의한 최근 동향과 영향 분석
기업/경쟁 분류
벤더 구도
기업 개요
- Puritan Medical Products
- Copan Diagnostics Inc.
- BD(Becton, Dickinson and Company)
- Thermo Fisher Scientific Inc.
- QuidelOrtho Corporation
- Longhorn Vaccines and Diagnostics, LLC
- Pretium Packaging
- Trinity Biotech
- Medical Wire &Equipment
- HiMedia Laboratories, LLC
- Hardy Diagnostics
- Wuxi NEST Biotechnology Co., Ltd.(Nest Scientific)
- VIRCELL SL
- DiaSorin SpA
- Titan Biotech

KSA

영문 목차

영문목차

Bacterial And Viral Specimen Collection Market Growth & Trends:

The global bacterial and viral specimen collection market size is anticipated to reach USD 33.37 billion by 2030 and expand at a CAGR of 14.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing burden of infectious diseases such as COVID-19, influenza, and tuberculosis has significantly increased the demand for bacterial and viral specimen collection. As healthcare systems strive to contain outbreaks and improve patient outcomes, governments and private sectors are ramping up healthcare investments. This surge in healthcare spending supports expanded diagnostic testing, better infrastructure, and the development of efficient specimen collection tools, ultimately driving market growth.

Technological advancements in diagnostics, including PCR, molecular assays, and rapid test platforms, have revolutionized the way infections are detected. These innovations require reliable and high-quality specimen collection methods to ensure accuracy. In addition, rising awareness among healthcare providers and patients about the importance of early and precise diagnosis increases testing volumes, thereby fueling demand for advanced specimen collection tools and boosting the overall market size.

The shift toward decentralized healthcare, driven by the convenience and accessibility of home testing and point-of-care diagnostics, is reshaping the specimen collection landscape. These trends reduce reliance on traditional lab settings and increase sample collection frequency. In addition, expanding research and clinical trials for vaccines, therapeutics, and infectious disease surveillance are boosting demand for standardized specimen collection kits, contributing significantly to the market's growth and broadening its application across various sectors.

Bacterial And Viral Specimen Collection Market Report Highlights:

By product, the viral specimen collection segment led the market with the largest revenue share of 57.3% in 2024, attributed to the rising prevalence of viral infections, including influenza, hepatitis, and emerging viral outbreaks.
By application, the diagnostics segment dominated the market with the largest share in 2024, driven by the growing demand for accurate and early disease detection.
The research segment is projected to witness significant growth from 2025 to 2030 due to technological advancements in diagnostic tools, such as next-generation sequencing and multiplex PCR, which enhance the accuracy and efficiency of specimen analysis.
The home testing segment is anticipated to be the fastest-growing segment during the forecast period, fueled by increasing consumer demand for convenient, private, and accessible diagnostic solutions.
North America accounted for the largest revenue share of 45% in 2024, propelled by the high prevalence of infectious diseases, substantial healthcare investments, advanced infrastructure, and robust research and development initiatives.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. End Use
- 1.2.4. Regional Scope
- 1.2.5. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.4.5. Details of Primary Research
1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Product Outlook
- 2.2.2. Application Outlook
- 2.2.3. End Use Outlook
- 2.2.4. Regional Outlook
2.3. Competitive Scenario

Chapter 3. Bacterial and Viral Specimen Collection Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Bacterial and Viral Specimen Collection Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrant
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
  - 3.3.2.1. Political Landscape
  - 3.3.2.2. Technological Landscape
  - 3.3.2.3. Economic Landscape

Chapter 4. Bacterial and Viral Specimen Collection Market: Product Estimates & Trend Analysis

4.1. Product Segment Dashboard
4.2. Bacterial and Viral Specimen Collection Market: Product Movement Analysis
4.3. Global Bacterial and Viral Specimen Collection Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
4.4. Bacterial Specimen Collection
- 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.4.2. Swabs
  - 4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.4.3. Bacterial Transport Media
  - 4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.4.4. Blood Collection Kits
  - 4.4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.4.5. Other Consumables
  - 4.4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Viral Specimen Collection
- 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.5.2. Swabs
  - 4.5.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.5.3. Viral Transport Media
  - 4.5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.5.4. Blood Collection Kits
  - 4.5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.5.5. Other Consumables
  - 4.5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Bacterial and Viral Specimen Collection Market: Application Estimates & Trend Analysis

5.1. Application Segment Dashboard
5.2. Bacterial and Viral Specimen Collection Market: Application Movement Analysis
5.3. Global Bacterial and Viral Specimen Collection Market Size & Trend Analysis, By Application, 2018 to 2030 (USD Million)
5.4. Diagnostics
- 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Research
- 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Bacterial and Viral Specimen Collection Market: End Use Estimates & Trend Analysis

6.1. End Use Segment Dashboard
6.2. Bacterial and Viral Specimen Collection Market: End Use Movement Analysis
6.3. Global Bacterial and Viral Specimen Collection Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
6.4. Hospitals & Clinics
- 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Home Testing
- 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6. Research Laboratories
- 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Bacterial and Viral Specimen Collection Market: Regional Estimates & Trend Analysis

7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Bacterial and Viral Specimen Collection Market by Region: Key Takeaways
7.4. North America
- 7.4.1. U.S.
  - 7.4.1.1. Key Country Dynamics
  - 7.4.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.1.3. Competitive Scenario
  - 7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.4.2. Canada
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.2.3. Competitive Scenario
  - 7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.4.3. Mexico
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.3.3. Competitive Scenario
  - 7.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5. Europe
- 7.5.1. U.K.
  - 7.5.1.1. Key Country Dynamics
  - 7.5.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.1.3. Competitive Scenario
  - 7.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.2. Germany
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.2.3. Competitive Scenario
  - 7.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.3. France
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.3.3. Competitive Scenario
  - 7.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.4. Italy
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.4.3. Competitive Scenario
  - 7.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.5. Spain
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.5.3. Competitive Scenario
  - 7.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.6. Denmark
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.6.3. Competitive Scenario
  - 7.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.7. Sweden
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.7.3. Competitive Scenario
  - 7.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.8. Norway
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.8.3. Competitive Scenario
  - 7.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Japan
  - 7.6.1.1. Key Country Dynamics
  - 7.6.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.1.3. Competitive Scenario
  - 7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.2. China
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.2.3. Competitive Scenario
  - 7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.3. India
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.3.3. Competitive Scenario
  - 7.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.4. Australia
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.4.3. Competitive Scenario
  - 7.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.5. Thailand
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.5.3. Competitive Scenario
  - 7.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.6.3. Competitive Scenario
  - 7.6.6.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.7.2.3. Competitive Scenario
  - 7.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.7.3.3. Competitive Scenario
  - 7.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.2.3. Competitive Scenario
  - 7.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.3.3. Competitive Scenario
  - 7.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.4.3. Competitive Scenario
  - 7.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.5.3. Competitive Scenario
  - 7.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/ Competition Categorization
8.3. Vendor Landscape
- 8.3.1. Key Company Heat Map Analysis, 2024
8.4. Company Profiles
- 8.4.1. Puritan Medical Products
  - 8.4.1.1. Company Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Strategic Initiatives
- 8.4.2. Copan Diagnostics Inc.
  - 8.4.2.1. Company Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Strategic Initiatives
- 8.4.3. BD (Becton, Dickinson and Company)
  - 8.4.3.1. Company Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Strategic Initiatives
- 8.4.4. Thermo Fisher Scientific Inc.
  - 8.4.4.1. Company Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Strategic Initiatives
- 8.4.5. QuidelOrtho Corporation
  - 8.4.5.1. Company Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Strategic Initiatives
- 8.4.6. Longhorn Vaccines and Diagnostics, LLC
  - 8.4.6.1. Company Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Strategic Initiatives
- 8.4.7. Pretium Packaging
  - 8.4.7.1. Company Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Strategic Initiatives
- 8.4.8. Trinity Biotech
  - 8.4.8.1. Company Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Strategic Initiatives
- 8.4.9. Medical Wire & Equipment
  - 8.4.9.1. Company Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Strategic Initiatives
- 8.4.10. HiMedia Laboratories, LLC
  - 8.4.10.1. Company Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Strategic Initiatives
- 8.4.11. Hardy Diagnostics
  - 8.4.11.1. Company Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Strategic Initiatives
- 8.4.12. Wuxi NEST Biotechnology Co., Ltd. (Nest Scientific)
  - 8.4.12.1. Company Overview
  - 8.4.12.2. Financial Performance
  - 8.4.12.3. Product Benchmarking
  - 8.4.12.4. Strategic Initiatives
- 8.4.13. VIRCELL SL
  - 8.4.13.1. Company Overview
  - 8.4.13.2. Financial Performance
  - 8.4.13.3. Product Benchmarking
  - 8.4.13.4. Strategic Initiatives
- 8.4.14. DiaSorin S.p.A.
  - 8.4.14.1. Company Overview
  - 8.4.14.2. Financial Performance
  - 8.4.14.3. Product Benchmarking
  - 8.4.14.4. Strategic Initiatives
- 8.4.15. Titan Biotech
  - 8.4.15.1. Company Overview
  - 8.4.15.2. Financial Performance
  - 8.4.15.3. Product Benchmarking
  - 8.4.15.4. Strategic Initiatives